PAP/PSA-expressing arenaviral vectors HB-302/HB-301

{
  "id": "MLC-T-ONC-015827",
  "term": "PAP/PSA-expressing arenaviral vectors HB-302/HB-301",
  "field": "Oncology and biomedicine",
  "definition": "An alternating, 2-vector replicating arenaviral combination agent composed of two genetically engineered replicating vectors: HB-301, which is based on the arenavirus lymphocytic choriomeningitis virus (LCMV), and HB-302, which is based on the arenavirus Pichinde virus (PICV), and both expressing the same transgenes encoding for the two prostate cancer-associated antigens prostatic acid phosphatase (PAP) and prostate specific antigen (PSA), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, the PAP/PSA-expressing arenaviral vectors HB-302/HB-301 express PSA and PAP peptides and cause antibody-mediated and cytotoxic T-lymphocyte (CTL)-mediated immune responses against prostate cancer cells expressing PSA and PAP.",
  "synonyms": [
    "PAP/PSA-expressing arenaviral vectors HB-300"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pap-psa-expressing-arenaviral-vectors-hb-302-hb-301/"
}